Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.

SG&A Expenses: Biopharma's Financial Pulse

__timestampSupernus Pharmaceuticals, Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 2014724710001244910
Thursday, January 1, 2015892040005029636
Friday, January 1, 20161060100004846776
Sunday, January 1, 20171379050005329003
Monday, January 1, 20181598880007121000
Tuesday, January 1, 20191584250009128000
Wednesday, January 1, 202020067700010731000
Friday, January 1, 202130475900010701000
Saturday, January 1, 202237722100016121000
Sunday, January 1, 202333636100037021000
Loading chart...

In pursuit of knowledge

Navigating SG&A Expenses: A Tale of Two Biopharma Companies

In the competitive landscape of biopharmaceuticals, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viking Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Supernus Pharmaceuticals has seen a staggering 364% increase in SG&A expenses, peaking in 2022. This growth reflects their aggressive market expansion and investment in operational infrastructure. In contrast, Viking Therapeutics, while maintaining a more conservative fiscal approach, has experienced a 2,873% surge in SG&A expenses, indicating a strategic shift towards scaling operations. Notably, 2023 marks a pivotal year for Viking, with expenses reaching their highest, suggesting a potential ramp-up in market activities. This comparative insight underscores the diverse strategies employed by these companies in navigating the complex biopharma sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025